Lipidor Ab (LIPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lipidor Ab (LIPI) has a cash flow conversion efficiency ratio of -0.130x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.11 Million ≈ $-227.39K USD) by net assets (Skr16.29 Million ≈ $1.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lipidor Ab - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Lipidor Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lipidor Ab debt and liabilities for a breakdown of total debt and financial obligations.
Lipidor Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipidor Ab ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Catenon S.A
MC:COM
|
0.241x |
|
Uniserve Communications Corp
V:USS
|
-0.065x |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
N/A |
|
Pasithea Therapeutics Corp
NASDAQ:KTTA
|
-0.237x |
|
Higher Way Electronic Co Ltd
TWO:3268
|
-0.040x |
|
Tuju Setia Bhd
KLSE:5297
|
-0.334x |
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Indivior PLC
LSE:INDV
|
-0.612x |
Annual Cash Flow Conversion Efficiency for Lipidor Ab (2016–2024)
The table below shows the annual cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Lipidor Ab.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr7.72 Million ≈ $831.01K |
Skr-16.08 Million ≈ $-1.73 Million |
-2.082x | -216.42% |
| 2023-12-31 | Skr-9.34 Million ≈ $-1.01 Million |
Skr-16.70 Million ≈ $-1.80 Million |
1.789x | +109.84% |
| 2022-12-31 | Skr2.15 Million ≈ $230.94K |
Skr-39.00 Million ≈ $-4.20 Million |
-18.174x | -5811.04% |
| 2021-12-31 | Skr43.52 Million ≈ $4.68 Million |
Skr-13.38 Million ≈ $-1.44 Million |
-0.307x | -28.15% |
| 2020-12-31 | Skr63.66 Million ≈ $6.85 Million |
Skr-15.27 Million ≈ $-1.64 Million |
-0.240x | +56.67% |
| 2019-12-31 | Skr26.83 Million ≈ $2.89 Million |
Skr-14.85 Million ≈ $-1.60 Million |
-0.554x | -185.21% |
| 2018-12-31 | Skr14.45 Million ≈ $1.55 Million |
Skr-2.81 Million ≈ $-301.86K |
-0.194x | +81.58% |
| 2017-12-31 | Skr3.48 Million ≈ $374.18K |
Skr-3.66 Million ≈ $-394.30K |
-1.054x | +76.02% |
| 2016-12-31 | Skr833.68K ≈ $89.72K |
Skr-3.66 Million ≈ $-394.30K |
-4.395x | -- |
About Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more